A major pandemic is sweeping the globe. Cases of COVID-19 are growing exponentially as people spread the disease throughout our connected world. Individuals and societal groups are reacting differently, looking for solutions to stem the threat to our health and way of life.
In the face of this threat, people are turning to governments for action, to the medical community for help, to the scientific community for answers, to commercial entities for products, to mass media for information, to social media for support, and to non-scientific organizations for miracles. In many ways, the pandemic is not just a test of our immune systems, but of what we hold valuable and where we put our trust.
Dr. Hendrix will talk about what we all want to know – what this is, what you can do about it, and what medical researchers are doing to try to find ways to combat the virus
Dr. Youngblood will talk about what has happened over the last few months, what is happening now, and how individuals and society are reacting to the pandemic, recognizing that this presentation and discussion is a snapshot of our collective experience that is ongoing and rapidly changing.
No one has “2020 hindsight” about what will happen next, but we will also talk about probable futures based on experiences in our past and the ability of the scientific approach to project future trends.
Specifics of Dr. Hendrix’s presentation:
— SARS-CoV-2 detection: basic molecular biology of the coronavirus, emphasizing detection targets of diagnostic tests for gene fragments using reverse transcriptase / polymerase chain reaction (PCR) techniques or antibody tests to detect convalescent states following initial infection
— COVID-19 (coronavirus disease): pathophysiology of cytokine explosion and acute respiratory distress syndrome (ARDS) and limitations of cytokine inhibitors
— Individual actions: strategies for avoidance and containment
— Potential treatments under evaluation:
> “borrowed” multi-drug regimens (drug re-positioning strategies) from other viral management protocols
> novel “off-schedule” application of drugs such as hydroxychloroquine (Plaquenil), a synthetic derivative of quinine, the first drug used effectively to treat malaria
> infusion of humoral antibodies (passive immunity) or inducing active immunity by vaccines targeting the Spike S-protein or capsid proteins
> pharmaceutical agents that target viral enzymes such as protease and RNA-replicase (potential “designer drugs”)
> Angiotensin Converting Enzyme (ACE)-II inhibitors to block virion access to cellular receptors
— COVID-19 (coronavirus disease): pathophysiology of cytokine explosion and acute respiratory distress syndrome (ARDS) and limitations of cytokine inhibitors
— Individual actions: strategies for avoidance and containment
— Potential treatments under evaluation:
> “borrowed” multi-drug regimens (drug re-positioning strategies) from other viral management protocols
> novel “off-schedule” application of drugs such as hydroxychloroquine (Plaquenil), a synthetic derivative of quinine, the first drug used effectively to treat malaria
> infusion of humoral antibodies (passive immunity) or inducing active immunity by vaccines targeting the Spike S-protein or capsid proteins
> pharmaceutical agents that target viral enzymes such as protease and RNA-replicase (potential “designer drugs”)
> Angiotensin Converting Enzyme (ACE)-II inhibitors to block virion access to cellular receptors
0 件のコメント:
コメントを投稿